Skip to main content
. 2016 Jan 7;7(5):6000–6014. doi: 10.18632/oncotarget.6830

Figure 4. The miR-3923 inhibitor rescued the inhibiting effects of LV-NUTF2P3-001-siRNA on PANC-1 cells.

Figure 4

(A) The expression of KRAS of PANC-1 treated with LV-NUTF2P3-001-siRNA or inh-3923 (100 nM) was examined by qRT-PCR. (B) Western blot analysis was performed to identify KRAS expression in transfected PANC-1 cells. Transfection with LV-NUTF2P3-001-siRNA decreased the expression of KRAS, which was further rescued by co-transfection with miR-3923 inhibitor. Relative intensity value is marked. (C) The inh-3923 reversed the inhibition of LV-NUTF2P3-001-siRNA on the viability of PANC-1 cells. (D) Matrigel invasion assays were performed to measure the invasive ability of PANC-1 cells treated with LV-NUTF2P3-001-siRNA and inh-3923 co-transfection. Results were quantified on the right. (E) Cell cycle distribution was measured by flow cytometry with PI staining. Increased S-phase proportion was observed in LV-NUTF2P3-001-siRNA treated group and further decreased after inh-3923 transfection. Contribution of different phases was shown on the right. All data were presented as means ± SD of at least three independent experiments. The p-value represents the comparison between groups (*p < 0.05, **p < 0.01,).